Sagimet's Cash Dwindles Amid Rising R&D, MASH & Acne Trials Advance

TL;DR

**Sagimet's cash is burning fast, making their clinical trial progress a high-stakes bet on future financing.**

AI Summary

Sagimet Biosciences Inc. reported a net loss of $12.908 million for the three months ended September 30, 2025, an improvement from a net loss of $14.619 million in the same period of 2024. However, the net loss for the nine months ended September 30, 2025, significantly widened to $41.470 million, compared to $29.366 million in the prior year, primarily due to increased research and development expenses, which rose to $32.320 million from $24.228 million. Cash and cash equivalents decreased sharply to $32.496 million as of September 30, 2025, from $75.840 million at December 31, 2024. The company initiated a Phase 1 clinical trial for denifanstat in combination with resmetirom for MASH in September 2025 and a first-in-human Phase 1 trial for TVB-3567 for acne in June 2025. Total assets declined to $128.401 million from $160.259 million, while total liabilities increased to $9.146 million from $4.454 million, indicating a deteriorating financial position. The company's lead candidate, denifanstat, received Breakthrough Therapy designation from the FDA for MASH and met all primary and secondary endpoints in a Phase 3 acne trial in China.

Why It Matters

Sagimet's significant cash burn, with cash and cash equivalents dropping from $75.840 million to $32.496 million in nine months, signals potential liquidity challenges for investors. The increased R&D spending, up to $32.320 million, is crucial for advancing its FASN inhibitors like denifanstat and TVB-3567, which could be game-changers in MASH and acne markets, but also exacerbates financial strain. For employees, continued funding is essential for job security and project continuity. Customers and the broader market await the success of denifanstat, especially given its Breakthrough Therapy designation for MASH, a highly competitive therapeutic area with major players like Madrigal Pharmaceuticals and Viking Therapeutics.

Risk Assessment

Risk Level: high — The company's cash and cash equivalents plummeted from $75.840 million at December 31, 2024, to $32.496 million at September 30, 2025, representing a 57% decrease. This rapid decline, coupled with a net loss of $41.470 million for the nine months ended September 30, 2025, indicates significant liquidity risk and a high probability of needing additional financing soon.

Analyst Insight

Investors should closely monitor Sagimet's cash position and future financing plans, as the current burn rate suggests a need for capital within the next few quarters. While clinical progress with denifanstat is promising, the financial runway is short, making any investment highly speculative until a clear funding strategy is articulated.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$128.401M

total Debt

N/A

net Income

-$41.470M

eps

-$1.28

gross Margin

N/A

cash Position

$32.496M

revenue Growth

N/A

Key Numbers

• $32.496M — Cash and cash equivalents (Decreased from $75.840M at Dec 31, 2024, indicating significant cash burn.)
• $41.470M — Net loss for nine months (Widened from $29.366M in the prior year, reflecting increased expenses.)
• $32.320M — Research and development expenses (Increased from $24.228M for the nine months, driving higher operating losses.)
• $12.908M — Net loss for three months (Improved from $14.619M in the same period of 2024.)
• 31,001,109 — Series A common stock outstanding (Increased from 30,674,855 shares at Dec 31, 2024.)
• $128.401M — Total assets (Decreased from $160.259M at Dec 31, 2024.)
• $9.146M — Total current liabilities (Increased from $4.454M at Dec 31, 2024.)
• $4,758 — Stock-based compensation expense (Increased from $3,754 for the nine months ended September 30, 2024.)

Key Players & Entities

• Sagimet Biosciences Inc. (company) — clinical-stage biopharmaceutical company
• denifanstat (drug_candidate) — lead drug candidate, FASN inhibitor for MASH, acne, and cancer
• TVB-3567 (drug_candidate) — second FASN inhibitor for acne
• U.S. Food and Drug Administration (regulator) — granted Breakthrough Therapy designation for denifanstat
• Ascletis BioScience Co. Ltd. (company) — license partner for denifanstat in China
• Nasdaq Global Market (market) — exchange where SGMT is registered
• resmetirom (drug_candidate) — thyroid hormone receptor beta (THR-) agonist combined with denifanstat for MASH
• Gannex Pharma Co., Ltd. (company) — affiliate of Ascletis BioScience Co. Ltd.

FAQ

Risk Factors

• Significant Cash Burn and Funding Needs [high — financial]: The company's cash and cash equivalents decreased from $75.840 million at December 31, 2024, to $32.496 million as of September 30, 2025. This substantial burn rate, coupled with increasing operating expenses, raises concerns about the company's ability to fund its ongoing research and development activities and clinical trials without additional financing.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: Sagimet is advancing multiple drug candidates through clinical trials, including denifanstat for MASH and TVB-3567 for acne. The success of these programs is subject to inherent risks, including the possibility of trial failures, unexpected side effects, and delays in obtaining regulatory approval from bodies like the FDA. The Breakthrough Therapy designation for denifanstat is positive but does not guarantee approval.
• Dependence on Key Drug Candidates [high — operational]: The company's future success is heavily reliant on the successful development and commercialization of its lead drug candidates, particularly denifanstat. Any setbacks in the development or regulatory pathway for denifanstat or other pipeline assets could have a material adverse impact on the company's financial condition and prospects.
• Deteriorating Financial Position [medium — financial]: Total assets have declined to $128.401 million from $160.259 million, while total current liabilities have increased to $9.146 million from $4.454 million. This trend, alongside a widening net loss for the nine-month period ($41.470 million in 2025 vs. $29.366 million in 2024), indicates a weakening financial standing.
• Competitive Landscape in MASH and Acne [medium — market]: The markets for MASH and acne treatments are competitive, with numerous established and emerging companies developing therapies. Sagimet faces competition from other drug developers, and the success of its candidates will depend on their ability to demonstrate superior efficacy, safety, and/or convenience compared to existing and pipeline alternatives.

Industry Context

Sagimet operates in the highly competitive biopharmaceutical sector, focusing on developing novel therapeutics for metabolic and inflammatory diseases. The MASH market is a significant area of unmet need, attracting substantial investment and research from numerous companies. Similarly, the dermatology space, particularly for acne treatments, is crowded with both established and emerging players, requiring innovative solutions to gain market share.

Regulatory Implications

The company's progress is heavily tied to regulatory approvals. The Breakthrough Therapy designation for denifanstat is a positive signal, but the path through Phase 1, 2, and 3 trials and final FDA approval remains complex and uncertain. Delays or failures in any stage can significantly impact timelines and financial resources.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate clinical trial progress and data readouts.
3. Assess competitive positioning in MASH and acne markets.

Key Dates

• 2025-09-30: Initiated Phase 1 clinical trial for denifanstat in combination with resmetirom for MASH — Represents progress in the development of a key drug candidate for a significant unmet medical need, potentially expanding its therapeutic application.
• 2025-06-30: Initiated first-in-human Phase 1 trial for TVB-3567 for acne — Marks the commencement of clinical testing for a new drug candidate, diversifying the company's pipeline and exploring new therapeutic areas.
• 2025-09-30: FDA granted Breakthrough Therapy designation for denifanstat for MASH — Indicates that the FDA believes denifanstat may demonstrate substantial improvement over available therapy for MASH, potentially accelerating its development and review process.
• 2025-09-30: Phase 3 acne trial in China met all primary and secondary endpoints — Provides strong positive clinical data for denifanstat in a specific indication, increasing confidence in its efficacy and potential for commercialization in that market.

Glossary

MASH

Metabolic dysfunction-associated steatohepatitis, a severe form of fatty liver disease. (Sagimet's lead drug candidate, denifanstat, has received Breakthrough Therapy designation for this indication, highlighting its importance to the company's pipeline.)

Breakthrough Therapy designation

A designation granted by the FDA to a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints. (This designation for denifanstat suggests a potentially faster regulatory pathway and increased likelihood of success for Sagimet's lead MASH candidate.)

Phase 1 clinical trial

The first stage of testing a new drug in a small group of people to assess its safety, determine a safe dosage range, and identify side effects. (Sagimet has initiated Phase 1 trials for denifanstat (in combination) and TVB-3567, indicating early-stage development progress.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any net earnings. It represents the total loss that has not been offset by profits. (Sagimet has an accumulated deficit of $336.781 million as of September 30, 2025, reflecting its history of operating losses.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par or stated value. (Sagimet has significant additional paid-in capital of $455.916 million, primarily from equity financing.)

Year-Over-Year Comparison

Compared to the prior year, Sagimet has seen a significant increase in its nine-month net loss, widening from $29.366 million to $41.470 million, primarily driven by a rise in R&D expenses from $24.228 million to $32.320 million. While the net loss for the three-month period improved slightly, the overall trend indicates increased investment in pipeline development. Total assets have decreased, and total liabilities have increased, signaling a more strained financial position. The company has also seen a substantial reduction in its cash reserves, from $75.840 million at year-end 2024 to $32.496 million as of September 30, 2025.

Key Financial Figures

• $0.0001 — ch registered Series A Common Stock, $0.0001 par value per share SGMT Nasdaq Glo

Filing Documents

• sgmt-20250930x10q.htm (10-Q) — 1656KB
• sgmt-20250930xex31d1.htm (EX-31.1) — 13KB
• sgmt-20250930xex31d2.htm (EX-31.2) — 14KB
• sgmt-20250930xex32d1.htm (EX-32.1) — 10KB
• 0001104659-25-110846.txt ( ) — 6566KB
• sgmt-20250930.xsd (EX-101.SCH) — 27KB
• sgmt-20250930_cal.xml (EX-101.CAL) — 32KB
• sgmt-20250930_def.xml (EX-101.DEF) — 165KB
• sgmt-20250930_lab.xml (EX-101.LAB) — 329KB
• sgmt-20250930_pre.xml (EX-101.PRE) — 249KB
• sgmt-20250930x10q_htm.xml (XML) — 1322KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page Item 1. Condensed Financial Statements 5 Condensed Balance Sheets (unaudited) 5 Condensed Statements of Operations and Comprehensive Loss (unaudited) 6 Condensed Statements of Stockholders' Equity (unaudited) 7 Condensed Statements of Cash Flows (unaudited) 8 Notes to Condensed Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 30

Signatures

Signatures 31 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) . All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: our financial performance; our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the scope, progress, results and costs of developing denifanstat, TVB-3567 or an

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements SAGIMET BIOSCIENCES INC. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except for share and per share amounts) As of September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 32,496 $ 75,840 Short-term marketable securities 84,197 75,410 Prepaid expenses and other current assets 2,787 1,524 Total current assets 119,480 152,774 Long-term marketable securities 8,806 7,408 Operating lease right-of-use assets 115 77 Total assets $ 128,401 $ 160,259 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,243 $ 1,425 Accrued expenses and other current liabilities 4,788 2,951 Operating lease liabilities 115 78 Total current liabilities 9,146 4,454 Commitments and contingencies (Note 6) Stockholders' equity: Undesignated preferred stock, $ 0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Series A common stock, $ 0.0001 per share: 500,000,000 shares authorized; 31,001,109 shares issued and outstanding at September 30, 2025; 30,674,855 shares issued and outstanding at December 31, 2024 3 3 Series B common stock, $ 0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Additional paid-in capital 455,916 450,883 Accumulated deficit ( 336,781 ) ( 295,311 ) Accumulated other comprehensive income 117 230 Total stockholders' equity 119,255 155,805 Total liabilities and stockholders' equity $ 128,401 $ 160,259 The accompanying notes are an integral part of these unaudited condensed financial statements. 5 Table of Contents SAGIMET BIOSCIENCES INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (in thousands, except for share and per share amounts) Three Months Ended Septe

View Full Filing

View this 10-Q filing on SEC EDGAR